Fenivir

Quick links to important sections

Fenivir

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fenivir

Quick Facts

Property Description
Active ingredient Penciclovir
Form Topical Cream (typically 1%)
Pharmacological class Antiviral Agent, Nucleoside Analog Inhibitor
Common use Localized viral infections (e.g., Herpes labialis)
Origin Synthetic acyclic guanine derivative

1. Fenivir: Identity and Pharmacological Classification

Fenivir is a pharmaceutical preparation distinguished by its primary component, the active ingredient, Penciclovir. This medicine belongs to the high-level class of antiviral agents, specifically categorized as a Nucleoside analog inhibitor, reflecting its molecular design to interfere with viral processes. The compound is a synthetic acyclic guanine derivative and is clinically recognized for its efficacy against viruses in the Herpes family, a finding supported by pharmacological studies. As a single-ingredient product, Fenivir is specifically positioned as a focused, topical treatment for the skin, differentiating it from systemic antiviral tablets.

2. Composition, Form, and General Purpose

The medication is most commonly presented as a topical cream intended for topical application to the affected area. This formulation, which typically contains 10 mg of Penciclovir per gram (a 1% concentration), is engineered to ensure localized action at the site of viral replication. Systemic drug exposure is negligible following this topical application, confirming its intended site-specific therapeutic action. The general purpose of this antiherpetic treatment is to limit the spread and mitigate the overall severity of localized viral infection. Penciclovir is the active form of a guanine analog with specific inhibitory activity against Herpes simplex virus types 1 and 2. This targeted action makes the preparation effective in managing common, localized outbreaks, such as those associated with Herpes labialis (cold sores).

What side effects are possible with Fenivir?

Possible Side Effects and Safety Information

The safety profile for Fenivir (Penciclovir topical cream) is defined by officially documented adverse reactions, which are primarily local and classified according to regulatory frequency standards.

Official Adverse Reactions by Frequency and System

Adverse reactions are grouped by the physiological system affected, consistent with regulatory classifications:

Classification System-Organ Class Example Reaction (as listed)
Common General Disorders, Skin Application site reactions (e.g., burning sensation, local pain, hypesthesia)
Infrequent Nervous System Taste perversion, headache
Not Known Immune System Hypersensitivity, allergic dermatitis, oropharyngeal edema

Common reactions are those most frequently reported in clinical trials and usually affect the area where the cream is applied. Reactions classified as Not Known are generally reported through post-marketing surveillance, where the precise frequency cannot be reliably estimated. This group includes clinically significant reactions such as oropharyngeal edema (swelling of the mouth/throat) and generalized hypersensitivity.

Safety Restrictions and Considerations

The official labeling includes specific restrictions on the use of this preparation. It is contraindicated in individuals with a known hypersensitivity to penciclovir, its precursor famciclovir, or any of its components. The cream is intended only for use on herpes labialis of the lips and surrounding face and is not recommended for application to mucous membranes. The safety and efficacy of the cream have not been established in children under 12 years of age or in immunocompromised patients, as noted in the official prescribing information.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation concerning Fenivir (penciclovir topical cream) consistently reports a minimal risk profile for overdose due to its formulation.

Documented Overdose Profile

Domain Official Regulatory Statement
Documented Manifestations The prescribing information states that there is no information on overdose specific to the topical cream. Adverse reactions related to ingestion are unlikely because the active ingredient is poorly absorbed following oral administration.
Physiological Systems Affected No specific systemic effects are documented in official labeling, which aligns with the finding of negligible systemic exposure following the recommended topical use.
Antidote and Treatment No specific antidote is known for penciclovir overdose. Management would consist of symptomatic and supportive treatment, a general measure described in regulatory guidance.
Monitoring Requirements No specialized hospital monitoring or observation requirements are documented due to the lack of evidence for systemic toxicity.

When Immediate Medical Help is Required

If accidental swallowing of the cream occurs, regulatory guidance requires seeking immediate medical attention or contacting a Poison Control center. This precautionary action is mandated by labeling requirements for topical products, even when systemic adverse events are considered unlikely.

The official documents define the overdose profile primarily by the minimal systemic risk inherent to the topical cream. As a result, the primary guidance is a requirement to contact emergency services promptly in the event of ingestion, rather than treating specific, documented, high-severity symptoms.

Therapeutic Uses of Fenivir

What Fenivir Treats: Main Uses and Benefits

Fenivir is commonly used to help manage the acute episodes of recurrent herpes labialis, the localized viral infection known as a cold sore or fever blister. This medication is generally used to help address conditions involving recurrent outbreaks on the lips and adjacent facial areas, and is commonly used across conditions presenting with acute episodes.

The cream is commonly applied in situations involving certain distressing symptoms. It helps address symptom clusters that may become intense or disruptive, such as the initial tingling, burning, and itching sensations, as well as managing the pain and discomfort of the visible blisters. This supportive relief contributes to improved comfort during periods of heightened symptoms. The primary therapeutic focus is on recurrent cold sores in adults and adolescents, and its use is considered relevant across acute therapeutic contexts.

“By assisting in the management of visible sores and supporting the alleviation of discomfort, Fenivir helps maintain a sense of stability and supports patients during difficult symptomatic phases.”

Quick Fact: Supportive Relief for Prodromal Discomfort

Property Description
Condition Category Recurrent Herpes Labialis (Cold Sores)
Symptom Focus Tingling, burning, pain, and discomfort
Therapeutic Support Supports easing overall episode duration
Target Group Immunocompetent adults and adolescents (12+)

Eligibility and Restrictions for Use

Who Can and Cannot Use Fenivir?

The population eligibility for Fenivir (penciclovir cream) is defined by official regulatory labeling, focusing on specific exclusions, age groups, and conditions of use.

Absolute Contraindications

The medicine is contraindicated and must not be used by any individual with a known hypersensitivity or allergy to the active ingredient, penciclovir, or any other component present in the cream formulation.

Age and Special Population Status

Fenivir is approved for use in adults and adolescents 12 years of age and older. The safety and effectiveness have not been established in pediatric patients less than 12 years of age. Furthermore, regulatory documents explicitly state that the effect (efficacy) has not been established in immunocompromised patients.

Conditional Use and Application Restrictions

Due to minimal systemic absorption, the cream has no special restrictions based on renal or hepatic function. For pregnant individuals, use is permitted only if clearly needed. The cream must be applied only to cold sores on the lips and face; application to human mucous membranes (such as inside the nose or mouth) or in or near the eyes is not recommended.

What should I know about interactions with other medicines?

Fenivir Interactions with other medicines and products

The official interaction profile for Fenivir (Penciclovir topical cream) is fundamentally structured by its pharmacokinetic characteristics, which result in a lack of documented, clinically relevant systemic drug interactions, as confirmed by authoritative governmental sources.


The regulatory assessment for this medicine confirms that the systemic absorption of the active ingredient, Penciclovir, is negligible following its application to the skin. This negligible systemic exposure means that the active substance levels reaching the bloodstream are too low to cause significant interaction effects with other medicines.

Consequently, official government regulatory documents, such as the U.S. Food and Drug Administration (FDA) prescribing information and the European Summary of Product Characteristics (SmPC), do not list specific pharmacokinetic or pharmacodynamic interactions.

Official Regulatory Interaction Statements

Due to the limited systemic availability, the official label text states that systemic drug interactions are unlikely. This results in several official conclusions regarding co-administration:

  • No Contraindicated Combinations: Regulatory labels do not identify any medicinal products that are formally prohibited for co-administration with Fenivir cream.
  • No Exposure Modification: There is no official documentation that other drugs increase or decrease the exposure of penciclovir via metabolic or transporter pathways.
  • No Timing Rules: The prescribing information does not specify mandatory administration timing separations between Fenivir and any other medication.

This profile defines the product’s official interaction structure by the absence of systemic risk, thus eliminating the need for complex interaction warnings typical of orally administered medicines.

Mechanism of Action

How Fenivir Works: The Antiviral Mechanism

The action of Fenivir operates through the pharmacodynamic properties of its active ingredient, Penciclovir, to interfere with the ability of the virus to complete DNA synthesis within infected cells.

Selective Activation by Viral Thymidine Kinase

Penciclovir's mechanism is selective because the drug remains inactive until it undergoes phosphorylation—a process initiated exclusively by the Viral Thymidine Kinase (vTK) enzyme. Since this enzyme is expressed by the virus, the drug is preferentially converted into its biologically active form within cells actively involved in viral replication. This selective conversion contributes to the drug's activity being localized to cells where viral replication is occurring.

Inhibition of Viral DNA Synthesis

Once activated, the drug is metabolized into Penciclovir triphosphate, which functions as a molecular mimic of the natural building blocks of DNA. This active metabolite competitively inhibits the Viral DNA Polymerase—the essential enzyme that synthesizes the virus's genetic material. By inserting itself into the growing viral DNA chain, the drug acts as a chain terminator, which rapidly arrests the assembly of the viral genome.

Mechanism-Driven Reduction in Local Propagation

By halting the creation of new viral DNA, the drug prevents the production and release of new infectious particles (virions) from the infected cells. This sustained molecular inhibition reduces the potential for new infectious particles to be released. The resulting physiological effect is a reduction in the creation of new infectious particles, which influences the magnitude of viral propagation within the tissue.

Dosage and Administration Information

Fenivir is administered as a 1% topical cream, a format designated for dermatologic application to the affected areas. This non-systemic approach dictates that the application is restricted solely to the lips and face, and the medicine is not intended for use on mucous membranes, such as the eyes or inside the mouth.

The usage protocol is characterized by an intensive, short-term course of action. The standard dosing schedule requires the application of a layer sufficient to fully cover the cold sore lesions and the surrounding symptomatic skin. This must be repeated every two hours while the individual is awake, resulting in approximately eight applications per day.

A crucial principle of administration is the timing of treatment initiation. Application must begin as early as possible—ideally during the first manifestation of symptoms, known as the prodrome, or immediately when the lesions appear. The entire treatment course is fixed at a duration of four days. Regarding specific populations, the use is established for adults and pediatric patients 12 years of age and older, all of whom follow the identical application schedule and duration.


Official Usage Summary

Category Administration Principle
Route & Site Topical use, restricted to lips and face
Frequency Every 2 hours while awake
Duration 4 days
Initiation Must begin at the earliest sign (prodrome)

Recent Clinical Evidence

Research Evidence / Overview of Studies for Fenivir

The clinical research concerning Fenivir, which contains the active ingredient penciclovir, was studied for managing acute outbreaks of cold sores. The core evidence comes from Randomized Controlled Trials (RCTs), which are used to determine if the product meets regulatory standards for its stated use.

Evidence for Use in Acute Cold Sore Episodes (Recurrent Herpes Labialis)

The core evidence comes from Randomized Controlled Trials (RCTs). These are studies where patients experiencing an acute cold sore episode were randomly assigned to use either the penciclovir cream or a non-medicated cream (known as a vehicle or placebo). These research scenarios were designed to explore short-term symptom changes and physical outcomes linked to inflammatory or irritative states.

Research examined specific patient-reported outcomes describing perceived discomfort, including the time to complete lesion healing and the duration of lesion-associated pain. The research describes that the data showed patterns related to a difference in the recorded time for complete healing and the duration of pain when compared to the placebo group. This research provides context, but does not determine whether an individual will respond similarly, as study results reflect the specific conditions under which they were conducted.

Comparison to Placebo and Other Topical Treatments

This part describes how the evidence examined the measured outcomes against an inactive cream (placebo) and describes the approach of studies that explored measured changes when compared to other topical treatments. In the key controlled trials, the cream was evaluated in trials when measured against an inactive vehicle cream.

Separately, research has explored the evidence by conducting systematic reviews and meta-analyses that combine findings from multiple controlled trials. These analyses, applied in studies examining patient-reported experiences, was observed in studies that described the measured outcomes when topical penciclovir was evaluated alongside other topical antiviral medications.

Populations Included in Clinical Trials

The research examined to support the regulatory approval of topical penciclovir focused predominantly on individuals defined as immunocompetent adults and adolescents (typically aged 12 years and older). These study populations were chosen from individuals who frequently experience recurrent cold sore episodes, which are conditions characterized by fluctuating or episodic manifestations. The results apply only to the populations studied and do not offer insight into other groups.

Limitations, Gaps, and Uncertainty in the Research Record

While controlled trials provide the main evidence, research also highlights what is known and what is still uncertain about the product. The systematic reviews and regulatory evaluations have also noted that the absolute magnitude of the measured change in healing time and symptom duration was described as small in some studies (often less than one day).

Additionally, there is insufficient evidence for certain groups. Clinical evaluation for the topical cream has not included or explored its use in populations with compromised immune systems. Therefore, research examining temporary physiological imbalance is lacking in this context, and there is limited information for long-term outcomes of topical penciclovir use in these patient groups. Comparative evidence is also lacking for certain groups, meaning findings are primarily related to the specific groups who participated in the original trials.

Frequently Asked Questions (FAQ)

Common questions about Fenivir (FAQ)

Q: Does Fenivir actually shorten the time a cold sore lasts?

Clinical studies submitted for regulatory review have shown that Fenivir cream may reduce the time it takes for cold sore lesions to heal completely compared to using a non-medicated cream. Research has also shown a reduction in the reported duration of pain associated with the cold sore episode.


Q: How quickly should I expect to see an improvement after starting to use Fenivir?

Official information details that clinical studies measured outcomes such as the time to complete healing and the duration of lesion-associated pain. While an exact time frame for the first perceived change is not specified in regulatory documents, the drug is formulated to begin working at a molecular level shortly after application to address the viral replication.


Q: Is it better to apply Fenivir at the very first sign of a tingle?

Official regulatory guidance emphasizes that treatment initiation is recommended as early as possible. This is ideally during the prodrome stage, which includes the first manifestation of symptoms, such as the tingling, itching, or redness that often precedes a visible cold sore.


Q: Can Fenivir prevent a cold sore from appearing if used early enough?

Official regulatory labeling indicates the product is for the treatment of recurrent herpes labialis. There is no claim that the cream prevents a cold sore outbreak from occurring, though early treatment is strongly recommended.


Q: Is there any research that confirms the speed of action for Fenivir?

Yes, research on the active ingredient, Penciclovir, describes its pharmacological properties. The drug's active form continues to work inside the infected skin cells to inhibit the virus's ability to replicate for an extended period after a single application.


Q: Does Fenivir make the cold sore less contagious?

The primary function of the cream is to inhibit the virus’s ability to multiply within the cells. By reducing the duration of viral shedding (the release of new infectious particles), the drug’s action may lower the potential for the virus to be spread from the lesion.


Q: Does using Fenivir regularly cause the virus to become resistant to the drug?

Official warnings note that an increased risk of the virus becoming resistant cannot be excluded for severely immunocompromised patients, such as transplant recipients. For individuals in these populations, consultation with a healthcare provider is recommended.


Q: What happens if I miss an application of Fenivir?

Patient information suggests that if an application is missed, it should be applied as soon as remembered. However, if it is nearly time for your next scheduled application, it is advised to skip the missed dose and return to the regular schedule. Do not apply a double dose to compensate for the missed one.


Q: Is it possible to use Fenivir too much?

Patient information advises against applying the cream more often or for a longer duration than what is specifically recommended in the directions. Always adhere to the established treatment course.


Q: Can Fenivir be used if the cold sore is already fully blistered or crusted?

While starting treatment at the very first symptom (like tingling) is ideal, clinical evidence indicates that the cream may still help to accelerate healing and reduce pain even if application is started later, after a blister or crust has already formed.


Q: Does Fenivir have an effect on future cold sore outbreaks?

Fenivir is officially indicated only for treating an active outbreak of recurrent herpes labialis. Official documents do not contain information regarding the cream's ability to prevent or alter the frequency of future cold sore occurrences.


Q: What should I do if I accidentally swallow a small amount of Fenivir?

Official patient safety information suggests contacting a poison control center or emergency medical services immediately if you suspect that the cream has been swallowed or an overdose has occurred.


Q: Is it true that Fenivir can only work if the cold sore is caused by the HSV-1 virus?

Laboratory studies have shown that the active ingredient, Penciclovir, exhibits antiviral activity against both Herpes Simplex Virus type 1 (HSV-1), which typically causes cold sores, and Herpes Simplex Virus type 2 (HSV-2).


Q: Why is it important to wash my hands before and after applying Fenivir?

Instructions derived from regulatory guidance specifically advise washing hands thoroughly with soap and water before and after applying the cream. This practice is intended to prevent the potential spread of the active viral infection to other areas of the body or to other people.


Q: Are there different strengths or formulations of Fenivir available?

Fenivir is supplied as a topical cream containing 1% of the active ingredient, Penciclovir. Official regulatory documentation details this single strength and dosage form.


Q: Is it normal to experience dryness around the lip area when using this cream?

The list of common side effects identified in clinical trials includes mild skin irritation and redness at the site of application. These local reactions may potentially lead to feelings of dryness or scaling in the treated area.


Q: Does the time of day I apply Fenivir matter for its effectiveness?

The official recommended application schedule specifies that the cream should be applied every two hours while the individual is awake. This pattern ensures consistent antiviral coverage during the time of day when most people are active.


Q: Why do people use Fenivir instead of just letting the cold sore heal naturally?

The cream is indicated to help accelerate the healing process of cold sores. In addition to speeding up healing, its use is intended to decrease the severity of associated symptoms such as pain, burning, tingling, or itching.


Q: Why is it often emphasized to apply Fenivir with a cotton swab rather than a finger?

Patient information derived from regulatory guidance highlights the need to take care to avoid transferring the virus from the cold sore to other parts of the body. Using a clean, disposable method, such as a cotton swab, helps ensure better hygiene and reduces the risk of self-inoculation.


Q: Is the cream absorbed systemically, or does it only work on the skin surface?

Regulatory testing confirmed that the systemic absorption of the active ingredient, Penciclovir, is minimal or negligible following its topical application to the skin. This means the drug primarily acts locally at the site of the cold sore and does not enter the bloodstream in significant amounts.


Q: Do I need a prescription to buy Fenivir, or is it available over the counter?

In the United States, official documentation from the FDA and NIH classifies this product as a Prescription Drug Label (Rx Only). This classification means that in the U.S., it requires a valid prescription from a licensed healthcare provider.


Q: Is there any difference in effectiveness between Fenivir branded cream and its generic equivalent?

For FDA-approved generic versions, they are required to meet the same regulatory standards for quality, safety, and effectiveness as the brand-name product. Generics must contain the same active ingredient, strength, and dosage form.

How should Fenivir be stored and disposed of?

How to Store and Dispose of Fenivir (Penciclovir Cream)

Fenivir cream must be stored under specific environmental conditions to maintain its integrity, as mandated by regulatory authorities.

Storage Requirements

Requirement Type Official Condition
Storage Temperature Controlled room temperature, between 20 C and 25 C (68 F and 77 F), with permitted excursions up to 30 C
Protection Keep from freezing and store away from excessive heat, moisture, and direct light.
Packaging Rule Must be kept in a closed container and the original packaging.
Child Safety Keep out of the sight and reach of children.

Disposal Instructions

Disposal must comply with environmental guidelines. Do not dispose of unused or expired Fenivir cream in wastewater (e.g., down a drain or toilet) or household trash. All unused product and waste material must be discarded in accordance with local requirements, typically by returning it to a pharmacist or designated collection point.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fenivir found in:

A-Z Index: